Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the stocks under $1 that will explode. On January 8, 2026, TheFly reported ...

Catalyst Pharmaceuticals recently announced that it was ranked 11th on Forbes’ 2026 list of America’s Most Successful ...

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Join Bristol Myers Squibb, Genentech, Google, J.P. Morgan, Novo Nordisk, Pappas Capital, Amazon Web Services, BIO, Members of ...

Biotech companies that will lead the next decade wont just have better science, theyll have superior operating models, writes ...

aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat ...

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ...

Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead candidate.

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies ...

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...